Christine M. Lovly

18.4k citations

143 papers · 6.8k indexed · 3 hit papers · h-index 44

Oncology top 0.5%
Molecular Biology top 2%
Pulmonary and Respiratory Medicine top 0.5%
Cancer Research top 1%
Epidemiology top 5%

Co-authors: Zhenfang Du Alice T. Shaw David Westover Wade T. Iams William Pao J. Zugazagoitia Luis Paz‐Ares Byoung Chul Cho
Topics: Lung Cancer Treatments and Mutations (89 papers)Cancer Genomics and Diagnostics (44 papers)Lung Cancer Research Studies (39 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Proceedings of the National Academy of Sciences Nature Medicine Nature Communications
Partner nations: United States United Kingdom Germany

In The Last Decade

Christine M. Lovly

136 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of receptor tyrosine kinase activation in cancer

2018 707 citations Zhenfang Du, Christine M. Lovly profile →
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

2018 518 citations David Westover, Christine M. Lovly et al. Annals of Oncology profile →
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

2023 75 citations Smruthy Sivakumar, Jay A. Moore et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Christine M. Lovly

Since Specialization

Citations

This map shows the geographic impact of Christine M. Lovly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine M. Lovly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine M. Lovly more than expected).

Fields of papers citing papers by Christine M. Lovly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine M. Lovly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine M. Lovly. The network helps show where Christine M. Lovly may publish in the future.

Co-authorship network of co-authors of Christine M. Lovly

This figure shows the co-authorship network connecting the top 25 collaborators of Christine M. Lovly. A scholar is included among the top collaborators of Christine M. Lovly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine M. Lovly. Christine M. Lovly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PP01.115 Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Mutations 2024 ·Journal of Thoracic Oncology ·Christina S. Baik,(unknown),Christine M. Lovly,Tejas Patil,Sonia S. Maruti,Stephen A. Stanhope,Stephan Herbertz,Misako Nagasaka	1
2	1298P Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD) 2024 ·Annals of Oncology ·(unknown),(unknown),Misako Nagasaka,Tejas Patil,Sonia S. Maruti,(unknown),(unknown),Stephan Herbertz,Christine M. Lovly	1
3	Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics 2024 ·Protein Science ·(unknown),Bhuminder Singh,Adam W. Smith,(unknown),Benjamin P. Brown,Christine M. Lovly,Allison S. Walker,Jens Meiler	3
4	Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformationbreakdown → 2023 ·Cancer Discovery ·Smruthy Sivakumar,Jay A. Moore,Meagan Montesion,Radwa Sharaf,Douglas I. Lin,Caterina I. Colón,(unknown),Ericka M. Ebot,Justin Y. Newberg,(unknown),(unknown),Quintin Pan,Afshin Dowlati,Garrett M. Frampton,Julien Sage,Christine M. Lovly	75
5	My Cancer Genome: Coevolution of Precision Oncology and a Molecular Oncology Knowledgebase 2021 ·JCO Clinical Cancer Informatics ·Marilyn Holt,Kathleen F. Mittendorf,Michele L. Lenoue-Newton,(unknown),Ingrid Anderson,Christine M. Lovly,Travis Osterman,Christine Micheel,Mia Levy	19
6	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation 2019 ·Clinical Cancer Research ·Benjamin P. Brown,Yunkai Zhang,David Westover,Yingjun Yan,Huan Qiao,Vincent Huang,Zhenfang Du,Jarrod A. Smith,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Lyudmila Bazhenova,Alexa B. Schrock,Jens Meiler,Christine M. Lovly	76
7	ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties 2018 ·Molecular Cancer Research ·(unknown),(unknown),Huiqin Chen,Wanleng Deng,Michael A. Davies,Christine M. Lovly	76
8	Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study 2018 ·Clinical Cancer Research ·Leora Horn,Jeffrey R. Infante,Karen L. Reckamp,George R. Blumenschein,Ticiana Leal,Saiama N. Waqar,Barbara J. Gitlitz,Rachel E. Sanborn,Jennifer G. Whisenant,Liping Du,Joel W. Neal,Jon P. Gockerman,Gary Dukart,Kimberly Harrow,Chris Liang,James J. Gibbons,(unknown),Christine M. Lovly,Heather A. Wakelee	131
9	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer 2017 ·Cancer Research ·Eiki Ichihara,David Westover,Catherine B. Meador,Yingjun Yan,Joshua A. Bauer,Lu Wang,Fei Ye,Amanda Kulick,Elisa de Stanchina,Robert McEwen,Marc Ladanyi,Darren A.E. Cross,William Pao,Christine M. Lovly	104
10	BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy 2017 ·Pigment Cell & Melanoma Research ·Douglas B. Johnson,(unknown),Zachary R. Chalmers,Garrett M. Frampton,Siraj M. Ali,Samuel M. Rubinstein,David Fabrizio,Jeffrey S. Ross,Sohail Balasubramanian,Vincent A. Miller,Philip J. Stephens,Jeffrey A. Sosman,Christine M. Lovly	28
11	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer 2016 ·Cancer Research ·Katherine Amato,Shan Wang,Li Tan,Andrew K. Hastings,Wenqiang Song,Christine M. Lovly,Catherine B. Meador,Fei Ye,Lu Wang,Justin M. Balko,Daniel C. Colvin,Justin Cates,William Pao,Nathanael S. Gray,Jin Chen	84
12	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies 2015 ·Cancer Immunology Research ·Douglas B. Johnson,Christine M. Lovly,Marisa Flavin,Katherine S. Panageas,Gregory D. Ayers,Zhiguo Zhao,Wade T. Iams,(unknown),(unknown),Charles R. Terry,Elizabeth Berry,A. John Iafrate,Ryan J. Sullivan,Richard D. Carvajal,Jeffrey A. Sosman	132
13	EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib 2015 ·Cancer Discovery ·Jean‐Nicolas Gallant,Jonathan H. Sheehan,Timothy M. Shaver,Mark Bailey,Doron Lipson,Raghu Chandramohan,Monica Red Brewer,Sally J. York,Mark G. Kris,Jennifer A. Pietenpol,Marc Ladanyi,Vincent A. Miller,Siraj M. Ali,Jens Meiler,Christine M. Lovly	81
14	Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer 2014 ·Molecular Cancer Therapeutics ·Catherine B. Meador,Hailing Jin,Elisa de Stanchina,Caroline A. Nebhan,Valentina Pirazzoli,Lu Wang,Huy Gia Vuong,Katherine E. Hutchinson,Peilin Jia,Xi Chen,Rosana Eisenberg,Marc Ladanyi,Katerina Politi,Zhongming Zhao,Christine M. Lovly,Darren A.E. Cross,William Pao	22
15	MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking 2014 ·Clinical Cancer Research ·Maria E. Arcila,Alexander Drilon,Brooke E. Sylvester,Christine M. Lovly,Laetitia Borsu,Boris Reva,Mark G. Kris,David B. Solit,Marc Ladanyi	106
16	Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions 2014 ·Cancer Discovery ·Christine M. Lovly,Abha A. Gupta,Doron Lipson,Geoff Otto,Tina Brennan,Catherine T. Chung,Scott C. Borinstein,Jeffrey S. Ross,Philip J. Stephens,Vincent A. Miller,Cheryl M. Coffin	303
17	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer 2013 ·Cancer Discovery ·Jim Sang,Jaime Acquaviva,Julie C. Friedland,Donald L. Smith,Manuel Sequeira,Chaohua Zhang,Qin Jiang,Liquan Xue,Christine M. Lovly,(unknown),Alice T. Shaw,Robert C. Doebele,Suqin He,Richard C. Bates,D. Ross Camidge,Stephan W. Morris,Iman El‐Hariry,David A. Proia	174
18	Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants 2012 ·Clinical Cancer Research ·Johannes M. Heuckmann,Hyatt Balke‐Want,Florian Malchers,Martin Peifer,Martin L. Sos,Mirjam Koker,Lydia Meder,Christine M. Lovly,Lukas C. Heukamp,William Pao,Ralf Küppers,Roman K. Thomas	201
19	Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors 2011 ·Cancer Research ·Christine M. Lovly,Johannes M. Heuckmann,Elisa de Stanchina,Heidi Chen,Roman K. Thomas,Chris Liang,William Pao	177
20	ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors 2011 ·Clinical Cancer Research ·Johannes M. Heuckmann,Michael Hölzel,Martin L. Sos,Stefanie Heynck,Hyatt Balke‐Want,Mirjam Koker,Martin Peifer,Jonathan M. Weiss,Christine M. Lovly,Christian Grütter,Daniel Rauh,William Pao,Roman K. Thomas	147

About Christine M. Lovly

Christine M. Lovly is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 143 papers that have together received 6.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (89 papers), Cancer Genomics and Diagnostics (44 papers) and Lung Cancer Research Studies (39 papers). The work is most often cited by research in Oncology (3.7k citations), Cancer Research (1.4k citations) and Pulmonary and Respiratory Medicine (3.1k citations). Christine M. Lovly has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Zhenfang Du, Alice T. Shaw, David Westover, Wade T. Iams, William Pao, J. Zugazagoitia, Luis Paz‐Ares, Byoung Chul Cho, Helen Piwnica‐Worms and Ryohei Katayama. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact